Latest News

Ridgefield, Conn. – Boehringer Ingelheim today announced results from an analysis of the SENSCIS®-ON trial. SENSCIS-ON is an open-label extension trial of the Phase III SENSCIS® study to assess the long-term tolerability and safety of Ofev® (nintedanib) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study also evaluated...
Researchers show that patients with central diabetes insipidus who lack anti-rabphilin-3A antibodies could be at a higher risk of tumor development Toyoake Aichi, Japan – Central diabetes insipidus (CDI), a rare condition involving the destruction or degeneration of neurons of the hypothalamic-posterior pituitary in the brain, has several likely underlying...
ATLANTA – New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies. VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in...
New Rochelle, NY – A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who were tested lacked neutralizing antibodies against either adeno-associated virus (AAV) 2 or AAV9. Click here to read the article now. NPC1 is a rare, fatal neurodegenerative...